GA=Geographic atrophy. AATD= Alpha-1 anti-trypsin deficiency. ARDS= Acute respiratory distress syndrome. HSCT-TMA= Hematopoietic stem cell transplant-associated thrombotic microangiopathy. BP= Blood pressure. PNH= Paroxysmal nocturnal hemoglobinuria.

SOLID TUMORS

Akari’s pipeline includes a novel pre-clinical antibody drug conjugate (“ADC”) candidate targeting Trophoblast antigen 2 (“Trop2”), which is an antigen broadly expressed in solid tumors of epithelial origin. Trop2 highly expressed in many cancers over and above that of levels observed in normal healthy tissue, making this protein a prime ADC target. Trop2 levels are elevated in several solid tumor cancers and Trop2 overexpression in metastatic tissues makes it an attractive and potential therapeutic target for late-stage diseases.

Geographic Atrophy (GA)

Akari’s pipeline includes pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA), a potentially blockbuster mass market indication. The company has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials for treatment of GA.